Two-Year US Pharmacovigilance Report on Brodalumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Two-Year US Pharmacovigilance Report on Brodalumab

Published:2020-12-18 Issue:1 Volume:11 Page:173-180
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Lebwohl Mark,Leonardi Craig,Wu Jashin J.,Armstrong April,Rawnsley Nicole,Merchant Mohammed,Alexander Binu,Jacobson Abby

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

http://link.springer.com/content/pdf/10.1007/s13555-020-00472-x.pdf

Reference17 articles.

1. Siliq [package insert]. Bridgewater, NJ: Bausch Health US, LLC. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label. Accessed 14 Dec 2020.

2. Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–28.

3. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86.

4. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181–9.

5. Papp K, Menter A, Leonardi C, et al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020. https://doi.org/10.1111/bjd.19132.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Injection site reactions resulting from the use of biological therapy in the treatment of moderate-to-severe plaque psoriasis;Expert Opinion on Drug Safety;2024-08-17

2. Brodalumab: 5-Year US Pharmacovigilance Report;Dermatology and Therapy;2024-05

3. Drug survival, effectiveness, and safety of brodalumab for moderate‐to‐severe psoriasis up to 3 years;International Journal of Dermatology;2024-01-29

4. Emerging treatment options for psoriatic arthritis;Revista Colombiana de Reumatología (English Edition);2023-07

5. Emerging treatment options for psoriatic arthritis;Revista Colombiana de Reumatología;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3